| Name | Title | Contact Details |
|---|
Headquartered in Lyndhurst, NJ, NAVAC was incorporated in 2017 to enter the industrial vacuum market as a high quality and high performance alternative to the more expensive and recognizable name brands. With a vision of leading the global market in both industrial vacuum and HVAC/R tools (including vacuum pumps), and having already achieved the latter in 2002, NAVAC will take advantage of continuous technical innovation, superior customer service, and the ability to offer levels of customization not often seen in the industry to achieve the same result for industrial vacuum. NAVAC is committed to establishing long-term, mutually beneficial relationships with our partners by building fair and open platforms for cooperation. As such, we already have a strong OEM business in the U.S. as suppliers to some of the most well known brands in the world. We can offer the same levels of service and customization to our NAVAC end users as well. We currently offer a full line of one- and two-stage oil-sealed rotary vane vacuum pumps and accessories. NAVAC is Your Ideal Vacuum Pump no matter what the application and we are committed to winning your business. We offer a full line of high-quality, competitively priced pumps. Most all models are stocked in our NJ warehouse. If we do not offer what you are looking for as standard, we want to work with you to develop the perfect solution.
Farmers Life Insurance Company ("Farmers Life") was founded in 1997 as a small credit life and disability insurance company and has flourished by providing secure insurance products that address a growing number of diverse consumer needs. In a fast-paced industry, we strive to deliver best-in-class service throughout the life of our policies ensuring that people can fund their retirements, secure their legacies and enjoy the peace of mind associated with a well-planned future.
Designers. Communicators. Team builders. We are Studio Tom, Dick & Harry: the creative internal communication specialists.
The Pipeline Group is a prominent provider of outsourced sales development solutions tailored for B2B technology companies. Founded in 2017 by Ken Jisser, the company is headquartered in San Jose, California, and has grown to employ between 300 and 410 people. It has been recognized as one of Americas fastest-growing private companies, ranking #415 by Inc. Magazine in 2020. The company operates on a bootstrapped model, generating revenue through private equity partnerships and customer referrals, with reported revenue of $63 million. The Pipeline Group offers an SDR-as-a-Service model, which includes dedicated remote sales teams for lead generation and pipeline acceleration. Their services are supported by proprietary technology that integrates data services and CRM tools, enhancing outreach efforts. They also provide temp-to-perm solutions to help clients manage SDR attrition and offer managed services such as content creation and campaign execution. The company emphasizes high-quality talent and guarantees outcomes based on activity volume and pipeline quality, supporting over 100 active partnerships with private equity firms and technology innovators.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.